The U.S. Centers for Disease Control and Prevention (CDC) will convene its vaccine advisory committee on June 25\u201326 for the first time since the panel was dissolved and reconstituted by Health Secretary Robert F. Kennedy Jr.\u2014a controversial move that introduced several members known for their opposition to certain vaccines.<\/p>\n
The reconstituted Advisory Committee on Immunization Practices (ACIP) is expected to deliberate on updated data and vote on multiple vaccine-related matters, including influenza, respiratory syncytial virus (RSV), and the use of thimerosal\u2014a mercury-based preservative historically used in some multi-dose vaccine vials.<\/p>\n
According to the CDC\u2019s published agenda, several widely administered vaccines from global pharmaceutical firms will be reviewed. Below is a summary of the products scheduled for discussion:<\/p>\n
Sanofi<\/strong><\/p>\n Fluzone Quadrivalent<\/em>: Approved in 2013 for individuals aged six months and older.<\/p>\n<\/li>\n Flublok Quadrivalent<\/em>: Approved in 2016 for adults 18+, replacing its trivalent predecessor.<\/p>\n<\/li>\n 2024 U.S. Sales<\/strong>: $1.66 billion.<\/p>\n<\/li>\n<\/ul>\n AstraZeneca\/MedImmune<\/strong><\/p>\n FluMist<\/em>: A nasal spray flu vaccine, FDA-approved in September 2024 for self-use in adults under 50 and for children 2\u201317 by a caregiver.<\/p>\n<\/li>\n 2024 Sales<\/strong>: $258 million.<\/p>\n<\/li>\n<\/ul>\n CSL Seqirus (CSL Ltd)<\/strong><\/p>\n Flucelvax<\/em>: A cell-based influenza vaccine approved in 2021.<\/p>\n<\/li>\n Afluria<\/em>: An egg-based vaccine approved in 2018.<\/p>\n<\/li>\n Fluad<\/em>: An adjuvanted vaccine approved in 2020.<\/p>\n<\/li>\n 2024 Combined Sales<\/strong>: $1.72 billion.<\/p>\n<\/li>\n<\/ul>\n Sanofi\/AstraZeneca<\/strong><\/p>\n Nirsevimab (Beyfortus)<\/em>: Approved in 2023 to protect infants against RSV.<\/p>\n<\/li>\n 2024 U.S. Sales<\/strong>: $1.24 billion.<\/p>\n<\/li>\n<\/ul>\n Merck<\/strong><\/p>\n Clesrovimab (Enflonsia)<\/em>: Recently approved in June 2025 for infants under one year during their first RSV season. Shipments are planned for the 2025\u20132026 cycle.<\/p>\n<\/li>\n<\/ul>\n GSK<\/strong><\/p>\n Priorix<\/em>: Approved for individuals aged one and older; can be administered in a two-dose regimen or as a booster.<\/p>\n<\/li>\n 2024 Global Sales<\/strong>: $439.96 million.<\/p>\n<\/li>\n<\/ul>\n Moderna<\/strong><\/p>\n mNEXSPIKE<\/em>: A next-generation vaccine approved in May 2025 for individuals aged 65+.<\/p>\n<\/li>\n Spikevax<\/em>: Initially approved in 2022, brought in $1.8 billion<\/strong> in 2024.<\/p>\n<\/li>\n<\/ul>\n Pfizer\/BioNTech<\/strong><\/p>\n Comirnaty<\/em>: Approved in August 2021 for people aged 16+.<\/p>\n<\/li>\n 2024 Sales<\/strong>: $5.35 billion.<\/p>\n<\/li>\n<\/ul>\n Novavax<\/strong><\/p>\n Nuvaxovid<\/em>: A protein-based vaccine approved in May 2025 for those 65+, after lengthy delays.<\/p>\n<\/li>\n 2024 Revenue<\/strong>: $682 million, including licensing and royalties.<\/p>\n<\/li>\n<\/ul>\n The upcoming CDC meeting marks a critical juncture in U.S. immunization policy, particularly given the ideological shift in the advisory panel’s composition. With several high-profile and commercially significant vaccines on the agenda, the meeting\u2019s outcomes may have substantial implications for public health strategy, regulatory oversight, and pharmaceutical market dynamics in the coming year.<\/p>\n","protected":false},"excerpt":{"rendered":" The U.S. Centers for Disease Control and Prevention (CDC) will convene its vaccine advisory committee on June 25\u201326 for the first time since the panel was dissolved and reconstituted by…<\/p>\n","protected":false},"author":1,"featured_media":6358,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[78],"tags":[],"class_list":["post-6356","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-regulatory"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/regtechafrica.com\/healthcare\/wp-content\/uploads\/2025\/06\/CDC-Advisory-Panel-to-Reevaluate-Key-Vaccines-Amid-Leadership-Shakeup-scaled.jpeg?fit=2560%2C1707&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/posts\/6356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/comments?post=6356"}],"version-history":[{"count":1,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/posts\/6356\/revisions"}],"predecessor-version":[{"id":6359,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/posts\/6356\/revisions\/6359"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/media\/6358"}],"wp:attachment":[{"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/media?parent=6356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/categories?post=6356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/tags?post=6356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n
\n
RSV Antibodies and Vaccines<\/strong><\/h3>\n
\n
\n
Measles, Mumps, Rubella (MMR)<\/strong><\/h3>\n
\n
COVID-19 Vaccines<\/strong><\/h3>\n
\n
\n
\n
Looking Ahead<\/strong><\/h3>\n